ArticleClinical and translational allergy2026
Steroid Sparing Effect of 300IR House Dust Mite Sublingual Immunotherapy Tablet in Mite Allergic Rhinitis.
Article in Clinical and translational allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02443805 (A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIn a large randomized controlled trial (NCT02443805) in moderate-to-severe house dust mite (HDM) allergic rhinitis (AR) patients with/without controlled asthma, the 300IR HDM sublingual immunotherapy (SLIT) tablet confirmed its efficacy in reducing symptoms and rescue medication (RM) use. This post hoc analysis aimed at assessing the potential steroid sparing effect of this tablet.
methodsParticipants receiving 300IR HDM SLIT-tablet or placebo for ∼12 months could use antihistamines (AH1), corticosteroids (CS - intranasal (INCS), or oral (OCS)) in a stepwise manner for subjective intolerable nasal/ocular symptoms. The proportions of patients and days with RM intake (overall and by drug class) were assessed over time and compared between groups (Chi-squared or Wilcoxon rank-sum tests). An odds that is, ratio of probability of using CS/probability of not using CS was calculated. Mean weekly CS doses were analyzed by ANCOVA.
resultsOf 1262 evaluable patients, ∼60% used at least one CS at baseline: 300IR = 373 and placebo = 396. During treatment, the proportions of patients using RM, oral AH1, and CS and of days with RM use decreased in both groups, systematically in favor of 300IR (p < 0.05 at end-of-treatment). Odds results indicated SLIT-patients were more likely not to use CS, whereas placebo-patients were more likely to use CS (p < 0.05 at end-of-treatment). After 12 months, 54% SLIT-patients were able to discontinue CS completely versus 42% placebo-patients (p = 0.0007). Those who were still using CS were taking fewer and lower doses than placebo-patients.
conclusionsIn moderate to severe HDM-AR patients, the 300IR HDM SLIT-tablet showed a steroid sparing effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.